ABSTRACT
Introduction Inconsistent effects of subthalamic deep brain stimulation (STN DBS) on pain, a common non-motor symptom of Parkinson’s disease (PD), may be due to variations in active contact location relative to a pain-reducing locus of stimulation.
Objective To distinguish the loci of maximal effect for pain and motor improvement in the STN region.
Methods We measured Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) Part I pain score (item-9), and MDS-UPDRS Part III motor score, preoperatively and 6-12 months after STN DBS. An ordinary least-squares regression model was used to examine active contact location as a predictor of follow-up pain score while controlling for baseline pain, age, dopaminergic medication, and motor improvement. An atlas-independent electric field model was applied to distinguish sites of maximally effective stimulation for pain and motor improvement.
Results In 74 PD patients, mean pain score significantly improved after STN DBS (p = 0.01). In a regression model, more dorsal active contact location was the only significant predictor of pain improvement (R2 = 0.17, p = 0.03). The stimulation locus for maximal pain improvement was lateral, anterior, and dorsal to that for maximal motor improvement.
Conclusions More dorsal STN DBS improves pain. Stimulation of the zona incerta, a region known to modulate pain in humans, may explain this observation.
Competing Interest Statement
KLC has received grant support from the NIH (NS107158), Parkinson Study Group (STEADY-PD III, SURE-PD3, NILO-PD, RAD-PD), Eli Lilly, Neuraly, and Voyager Therapeutics. He has served as a consultant to Abbott, Accordant, Avion Pharmaceuticals, CNS Ratings, Neurocrine, and Watermark Research Partners. He has received royalties from UpToDate and Springer Publishing. KJW has received grant support from Parkinson Study Group and Eli Lilly, and royalties from UpToDate. PGP has received grant support from NIH and NSF and Taubman Medical Research Institute. He is on the scientific advisory board of NeuroOne.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MEDIRB of the University of Michigan gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial disclosures and conflicts of interest related to manuscript: KLC has received grant support from the NIH (NS107158), Parkinson Study Group (STEADY-PD III, SURE-PD3, NILO-PD, RAD-PD), Eli Lilly, Neuraly, and Voyager Therapeutics. He has served as a consultant to Abbott, Accordant, Avion Pharmaceuticals, CNS Ratings, Neurocrine, and Watermark Research Partners. He has received royalties from UpToDate and Springer Publishing.
KJW has received grant support from Parkinson Study Group and Eli Lilly, and royalties from UpToDate.
PGP has received grant support from NIH and NSF and Taubman Medical Research Institute. He is on the scientific advisory board of NeuroOne.
Funding sources: None
Data Availability
All data produced in the present study are available upon reasonable request to the authors and IRB approval
